JPMorgan Chase & Co. Sells 14,567 Shares of Genmab A/S (NASDAQ:GMAB)

JPMorgan Chase & Co. decreased its stake in Genmab A/S (NASDAQ:GMAB - Free Report) by 53.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 12,943 shares of the company's stock after selling 14,567 shares during the period. JPMorgan Chase & Co.'s holdings in Genmab A/S were worth $316,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Blue Trust Inc. raised its stake in Genmab A/S by 892.0% during the 3rd quarter. Blue Trust Inc. now owns 4,315 shares of the company's stock valued at $108,000 after acquiring an additional 3,880 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in Genmab A/S by 43.6% in the third quarter. Allspring Global Investments Holdings LLC now owns 4,653 shares of the company's stock worth $113,000 after purchasing an additional 1,413 shares during the period. Mount Yale Investment Advisors LLC bought a new position in Genmab A/S in the 3rd quarter valued at about $192,000. Signaturefd LLC increased its stake in Genmab A/S by 32.1% during the 3rd quarter. Signaturefd LLC now owns 7,900 shares of the company's stock valued at $193,000 after buying an additional 1,920 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of Genmab A/S by 63.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,064 shares of the company's stock worth $197,000 after buying an additional 3,137 shares in the last quarter. Institutional investors and hedge funds own 7.07% of the company's stock.

Genmab A/S Price Performance

NASDAQ GMAB traded down $0.56 on Monday, hitting $19.11. 1,291,015 shares of the stock were exchanged, compared to its average volume of 1,574,863. The company has a market capitalization of $12.65 billion, a price-to-earnings ratio of 18.55, a P/E/G ratio of 0.55 and a beta of 0.96. Genmab A/S has a 52-week low of $19.00 and a 52-week high of $31.88. The company's 50-day moving average price is $21.02 and its two-hundred day moving average price is $23.67.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing analysts' consensus estimates of $0.32 by ($0.03). Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. The business had revenue of $816.10 million during the quarter, compared to analyst estimates of $838.20 million. During the same quarter in the prior year, the company earned $0.47 EPS. Equities analysts predict that Genmab A/S will post 1.25 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. HC Wainwright reiterated a "buy" rating and set a $50.00 price objective on shares of Genmab A/S in a research note on Thursday, January 23rd. Redburn Atlantic assumed coverage on Genmab A/S in a research note on Tuesday, October 8th. They set a "buy" rating for the company. Sanford C. Bernstein upgraded shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Friday, December 20th. Finally, BMO Capital Markets reiterated an "outperform" rating and issued a $48.00 target price (up from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $45.20.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.